Hakmin Lee1, Cheol Kwak1, Hyeon Hoe Kim1, Seok-Soo Byun1, Sang Eun Lee1, Sung Kyu Hong2. 1. Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Department of Urology, Seoul National University Hospital (CK, HHK), Seoul, Republic of Korea. 2. Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Department of Urology, Seoul National University Hospital (CK, HHK), Seoul, Republic of Korea. Electronic address: skhong@snubh.org.
Abstract
PURPOSE: Controversy continues about the prognostic significance of diabetes mellitus in patients with renal cell carcinoma. We investigated the relationship between diabetes mellitus and prognosis in patients with renal cell carcinoma who underwent surgical treatment. MATERIALS AND METHODS: We reviewed data on 3,075 consecutive patients treated with radical or partial nephrectomy for nonmetastatic renal cell carcinoma from 1988 to 2013. The propensity score of a diabetes mellitus history was calculated and 417 patients with diabetes were matched to 814 without diabetes in a 1:2 ratio. The potential association of preexisting diabetes and preoperative HbA1c with outcomes was tested. Univariate and multivariate analyses were performed to identify independent predictors of progression-free, cancer specific and overall survival. RESULTS: Before matching, patients with diabetes showed worse prognosis in terms of progression-free, overall and cancer specific survival (each p<0.001). In matched cohorts 1,231 patients with diabetes showed progression-free (p=0.001), cancer specific (p<0.001) and overall survival (p<0.001) inferior to that in patients without diabetes. On multivariate analyses diabetes was an independent predictor of disease progression (HR 1.766 p=0.002), all cause mortality (OR 1.825, p=0.001) and cancer specific mortality (HR 2.266, p=0.001). Among patients with diabetes who had available preoperative HbA1c data high HbA1c independently predicted postoperative disease progression (HR 2.221, p=0.023). CONCLUSIONS: Diabetes mellitus is an independent predictor of cancer specific and overall survival in patients who undergo surgery for renal cell carcinoma. Also, in patients with diabetes mellitus poor glycemic control is associated with a higher risk of progression.
PURPOSE: Controversy continues about the prognostic significance of diabetes mellitus in patients with renal cell carcinoma. We investigated the relationship between diabetes mellitus and prognosis in patients with renal cell carcinoma who underwent surgical treatment. MATERIALS AND METHODS: We reviewed data on 3,075 consecutive patients treated with radical or partial nephrectomy for nonmetastatic renal cell carcinoma from 1988 to 2013. The propensity score of a diabetes mellitus history was calculated and 417 patients with diabetes were matched to 814 without diabetes in a 1:2 ratio. The potential association of preexisting diabetes and preoperative HbA1c with outcomes was tested. Univariate and multivariate analyses were performed to identify independent predictors of progression-free, cancer specific and overall survival. RESULTS: Before matching, patients with diabetes showed worse prognosis in terms of progression-free, overall and cancer specific survival (each p<0.001). In matched cohorts 1,231 patients with diabetes showed progression-free (p=0.001), cancer specific (p<0.001) and overall survival (p<0.001) inferior to that in patients without diabetes. On multivariate analyses diabetes was an independent predictor of disease progression (HR 1.766 p=0.002), all cause mortality (OR 1.825, p=0.001) and cancer specific mortality (HR 2.266, p=0.001). Among patients with diabetes who had available preoperative HbA1c data high HbA1c independently predicted postoperative disease progression (HR 2.221, p=0.023). CONCLUSIONS:Diabetes mellitus is an independent predictor of cancer specific and overall survival in patients who undergo surgery for renal cell carcinoma. Also, in patients with diabetes mellitus poor glycemic control is associated with a higher risk of progression.
Authors: Agnieszka Karbownik; Anna Stachowiak; Hanna Urjasz; Katarzyna Sobańska; Agnieszka Szczecińska; Tomasz Grabowski; Joanna Stanisławiak-Rudowicz; Anna Wolc; Edmund Grześkowiak; Edyta Szałek Journal: Pharmacol Rep Date: 2020-01-08 Impact factor: 3.024
Authors: Johannes C van der Mijn; Bashir Al Hussein Al Awamlh; Aleem Islam Khan; Lina Posada-Calderon; Clara Oromendia; Jonathan Fainberg; Mark Alshak; Rahmi Elahjji; Hudson Pierce; Benjamin Taylor; Lorraine J Gudas; David M Nanus; Ana M Molina; Joseph Del Pizzo; Douglas S Scherr Journal: PLoS One Date: 2019-12-09 Impact factor: 3.240
Authors: Jacek Rysz; Beata Franczyk; Janusz Ławiński; Robert Olszewski; Anna Gluba-Brzózka Journal: Int J Mol Sci Date: 2020-09-30 Impact factor: 5.923